Drugs / MGTA-145
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04154670 | Nov 2019 → Mar 2020 | impaired renal function disease | Ensoma | Completed | No outcome recorded |
| Phase 1 | NCT03932864 | Apr 2019 → Feb 2020 | — | Ensoma | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT05445128 | Jun → Dec 2022 | sickle cell disease | Ensoma | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04762875 | Jun → Sep 2021 | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Ensoma | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04552743 | Oct 2020 → Jul 2021 | plasma cell myeloma | Surbhi Sidana, MD | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGTA-145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05445128 ↗ |
| Known as | GROβT | “MGTA-145 or GROβT, a CXCR2 agonist, has shown promising activity for hematopoietic stem cell (HSC) mobilization with plerixafor in pre-clinical studies and healthy volunteers.” PMID 39384609 ↗ Oct 2024 |
| Action | Activate | “A chemokine receptor type 2 (CXCR2) agonist protein” NCT04552743 ↗ |
| Modality | Protein / enzyme biologic | “A chemokine receptor type 2 (CXCR2) agonist protein” NCT04552743 ↗ |
| Route | Intravenous | “MGTA-145 will be given in various doses intravenously” NCT03932864 ↗ |
| Target | CXCR2 | “A chemokine receptor type 2 (CXCR2) agonist protein” NCT04552743 ↗ |